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Abstract 
Introduction 
Placenta previa is a severe pregnancy complication with considerable maternal and neonatal morbidity. 
Placenta previa can be defined as major or minor by location. Major placenta previa is associated with 
higher complication rates. Management of women with minor placenta previa has not been well defined. 
The primary goal of the study was to evaluate the accuracy of our existing screening protocol for placenta 
previa. Secondly, we wanted to compare pregnancy and delivery outcomes by the type of placenta previa.  
Methods 
The study was conducted at the Helsinki University Hospital between June 2010 and September 2014. 
The study population consisted of all women with the antenatal ultrasound diagnosis of placenta previa 
during delivery. Data were retrospectively collected and analysed.  
Results 
Altogether 176 women had placenta previa at delivery (major 129, minor 47). Placenta previa remained 
undiagnosed at second trimester screening ultrasound in 32 women (18.2%). Twenty (62.5%) of these 
cases had minor placenta previa and 12 (37.5%) had major placenta previa. Five (15.6%) of the 
undiagnosed cases developed life-threatening hemorrhage (≥ 2500 ml) during the delivery and two had 
abnormally invasive placenta followed by hysterectomy. Women with major placenta previa had 
significantly more blood loss and delivered earlier than women with minor placenta previa. The groups 
were otherwise similar, including the rate of abnormally invasive placenta.  
Discussion 
The existing protocol for placenta previa missed almost one fifth of cases. Both major and minor placenta 
previa are risk factors for abnormally invasive placenta and should be treated as severe conditions. 
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Introduction 
Placenta previa (PP) occurs in approximately 0.5% of all pregnancies and causes maternal and neonatal 
morbidity [1-5]. The incidence of PP is increasing due to increasing cesarean section (CS) rates, advanced 
maternal age, use of artificial reproductive technologies, smoking, and cocaine use during pregnancy 
[1,3]. PP is also a major risk factor for placenta accreta, which increases the risk of life-threatening 
hemorrhage, hysterectomy, and surgical complications [1,6-11]. 
Placenta accreta is a general term for placenta accreta spectrum disorders or for morbidly adherent 
placenta [8,11]. In this study we decided to use the term abnormally invasive placenta (AIP) introduced 
by the International Society for AIP [9]. This definition includes both adherent and invasive (increta and 
percreta) placenta types. Drawing line between these subtypes is not always easy, especially in the 
clinical situations when the invasiveness of the placenta is not known before the delivery [12].  
PP can be defined as major or minor by the location of placental edge [10,13]. In major PP, the placenta 
overlaps the internal cervical os completely or partially, while minor PP is located <20 mm from the 
internal cervical os [10,13]. Minor PP is also defined as low-lying or marginal PP [10,11] (Figure 1). 
Major PP is associated with higher complication rates than minor PP [13-16]. Women with major PP 
have more antepartum and postpartum hemorrhage, preterm deliveries, AIP, and hysterectomies than 
women with minor PP [13-16].  
The need for follow-up of minor PP is controversial [17-21]. Taipale et al. recommended confirmatory 
transvaginal ultrasound if PP was suspected by transabdominal ultrasonography in mid-pregnancy and a 
follow-up scan at 26 to 30 gestational weeks only if the placenta covered cervical os ≥ 15 mm [19]. On 
the other hand, two more recent studies recommended follow-up also for women with minor PP [20,21]. 
Our primary goal was to evaluate the performance of our existing screening protocol. Secondly, we 
wanted to compare pregnancy and delivery outcomes by the type of PP.  
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Methods 
This retrospective cohort study was conducted at the Helsinki University Hospital and included all 
women who had the diagnosis of PP at the time of delivery between June 2010 and September 2014. The 
total number of deliveries annually during the study period varied between 4500 and 5500. The 
participants were identified from the hospital database by using specific ICD-10 diagnosis codes (O44.0 
and O44.1). The study was approved by the Ethics Committee of the Helsinki University Hospital 
(number140/13/03/03/2012). 
Finnish law guarantees (since year 2007) to each woman two voluntary and free-of-charge prenatal 
screening examinations for fetal aneuploidies and structural anomalies. Most screening examinations are 
performed by trained midwives and only high-risk pregnancies are followed by a maternal and fetal 
medicine specialist [22]. The uptake of the screening program is approximately 95% in the Helsinki 
metropolitan area (personal communication, Vedran Stefanovic, corresponding author, unpublished).  
At the time of the screening for fetal structural anomalies, the placental position is also determined. The 
screening protocol for PP (Figure 2) in our unit is based on the study of Taipale et al. [19]. Therefore, 
only a proportion of the women with major PP and none of the women with minor PP have been offered a 
follow-up scan after the second trimester screening ultrasound. 
PP diagnosis code was set when the obstetrician first time confirmed the existence of PP by ultrasound 
examination (usually at 28-30 gestational weeks´ follow-up visit), or at any time when a woman was 
admitted to hospital due to bleeding and PP was diagnosed in women without the previously suspected 
PP.  
Data on maternal baseline characteristics and pregnancy outcomes were collected retrospectively. The 
type of PP was determined by the most recent ultrasound examination before delivery. Additionally, the 
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occurrence of hemorrhage and other complications related to PP and the treatment modalities used for 
these complications were recorded. 
The main outcome measure was the accuracy of the mid-pregnancy ultrasound screening protocol to 
predict PP at the time of the delivery. The outcomes of major and minor PP were compared.  
For this study, AIP cases were identified according to EW-AIP (European Working Group on 
Abnormally Invasive Placenta) recommendations [9]. Clinical diagnosis of AIP was set if the placenta 
could not be removed without massive hemorrhage. All the women with hysterectomy had a 
histopathological examination performed. The management protocol of PP cases with or without 
suspected AIP is shown below. 
 
Treatment protocol for women with PP without suspected AIP 
Antenatal diagnosis of PP was established by ultrasound either at the time of the second trimester fetal 
structural anomaly screening performed between 18+0 and 21+6 gestational weeks or at any time later in 
pregnancy upon admission to hospital. Most of the screening ultrasounds were performed 
transabdominally. Transvaginal ultrasound was performed if PP was suspected. No follow-up visits after 
screening were offered if the placenta overlapped the internal cervical os ≤ 14 mm. For women with 
placenta overlapping the cervix ≥ 15 mm, a follow-up visit was scheduled at 28 to 30 gestational weeks. 
If PP still persisted, further follow-up visits were scheduled at 34 and 36 gestational weeks.  
In the absence of bleeding episodes, the time and the mode of delivery were determined during the 
follow-up visit at 36 gestational weeks. If the placental edge was 1 to 20 mm above the internal cervical 
os, vaginal delivery was recommended. Otherwise, the preferred mode of delivery was elective CS. At the 
beginning of the study period (until the end of 2011), elective CS was planned at 38 to 39 gestational 
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weeks and at 37 gestational weeks from the beginning of 2012. If a woman did not have bleeding 
episodes after follow-up visit at 36 gestational weeks, ultrasound was not routinely repeated. 
If a woman was admitted to hospital due to hemorrhage, a detailed assessment of the fetal biophysical 
profile and an assessment of placental function and position were performed by ultrasound. Antenatal 
steroids were administered upon admission if bleeding was severe and gestational age was < 35+0 weeks. 
If bleeding did not require immediate delivery and had ceased within a few days, women were treated as 
outpatients. Hospitalization was considered necessary with recurrent bleeding episodes.  
 
Treatment protocol for women with PP and antenatally suspected AIP 
The presence of AIP was estimated at the follow-up visit at 28 to 30 gestational weeks. MRI imaging was 
performed if AIP was suspected by ultrasound. Follow-up visits were scheduled in every two weeks. 
Corticosteroids were administrated routinely at 33 gestational weeks or earlier if bleeding occurred. 
Elective CS was planned at 34 to 35 gestational weeks in an operating room equipped with interventional 
radiology capabilities. Occlusion balloons were placed in the iliac arteries and ureter stents were also 
placed before the CS. After delivery a gentle attempt of manual placental removal was performed. If this 
failed, placenta was either left in situ or emergency hysterectomy was performed. Embolization was 
performed in selected cases. A histopathological examination of hysterectomy specimens was performed. 
 
Statistics 
Statistical analysis was performed using SPSS statistical package (SPSS Inc., Chicago, IL, USA). The 
chi-squared test or Fisher’s exact test was used for comparison of categorical variables between groups. 
Continuous variables were analysed by Mann-Whitney U test after Shapiro-Wilk test evaluation of data 
normality. A test value p < 0.05 was considered statistically significant.  
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Results 
PP was diagnosed in 176 women at the time of the delivery. Major PP was diagnosed in 129 (73.3%) 
women and minor PP in 47 (26.7%) women (Figure 3). 
The baseline characteristics by the type of PP are shown in Table 1. Sixty-three women were primiparous 
(35.8%) and 45 (71.4%) had one or more risk factor for PP.  
Overall, 32 women (18.2%) with PP at the time of delivery were not identified at 18 to 22 gestational 
weeks by our second trimester screening protocol (Table 2). Their PP was diagnosed later in pregnancy 
upon admission to hospital due to contractions or hemorrhage. Twenty (62.5%) women had minor PP and 
12 (37.5%) women had major PP. Twenty-nine (90.6%) of the 32 women whose PP was undiagnosed at 
second trimester screening had bleeding episodes during the pregnancy. Seven (21.9%) of the 32 had the 
first bleeding episode ≥ 37 gestational weeks. Five women (15.6%) had life-threatening hemorrhage (≥ 
2500 ml) at the time of the delivery. Emergency CS was performed in 13 women (40.6%). Two women 
with undiagnosed PP at second trimester screening had hysterectomy performed. Both women had AIP 
and a history of previous CS.  
AIP was confirmed in 26 women at the time of the delivery either clinically or by a histopathological 
examination of a hysterectomy specimen (Table 3).  Twenty-five cases of placenta accreta and one case 
of placenta precreta were found. Sixteen (61.5%) of the AIP cases were diagnosed antenatally. One 
women with AIP was primiparous and had no risk factors. Six of the ten women whose AIP remained 
undiagnosed antenatally had minor PP. Thirteen (50%) of the 26 women had life-threatening hemorrhage 
(≥ 2500 ml). Altogether 15 hysterectomies were performed. All these women had AIP confirmed by a 
histopathological examination of a hysterectomy specimen and 13 had history of CS.  
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The comparison of the outcomes of women with major and minor PP is shown in Table 4. At the time of 
delivery, women with major PP had significantly more blood loss than women with minor PP (median 
1310 ml vs. 850 ml). Women with major PP also delivered earlier than women with minor PP. There 
were otherwise no differences between the groups. AIP was equally common (minor PP 14.9% vs. major 
PP 14.7%). 
 
Discussion 
There are three important findings in this study. First, almost one fifth of women with major or minor PP 
remained undiagnosed during the second trimester screening ultrasound. Second, we observed that 
although the blood loss was heavier and preterm birth was slightly more common among women with 
major PP, the rate of other adverse pregnancy outcomes and postpartum complications was similar 
regardless of the type of PP. The third important finding was that the rate of AIP was similar in cases with 
major or minor PP. 
PP was often missed in our study and almost 40% of the undiagnosed cases were major PPs. This 
suggests that a substantial proportion of women with placenta overlapping cervical os (1-14 mm) at mid-
pregnancy have major PP at term. In the study of Taipale et al., the positive predictive value for PP at 
delivery was 19% with 100% sensitivity if the placental edge was ≥ 15 mm over cervical os at 18 to 23 
weeks of gestation [19]. Additionally, Heller et al. reported the placental resolution rate to be as high as 
98.4% in minor PP [18].  
Lal et al. demonstrated that women with prior CS and major PP diagnosed at the mid-pregnancy 
screening are less likely to show resolution of PP [23]. In their study, resolution occurred in 61% of 
women with a prior CS and in 90% of women who did not have prior CS [23]. Laughon et al. reported 
that a history of CS was associated with a three-fold increased risk for PP at the time of the delivery [24]. 
Prior CS is an independent risk factor both in women with major or minor PP [23,24]. These women are 
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also at increased risk for AIP [8]. Two women whose pregnancy resulted in hysterectomy due to AIP had 
no follow-up scheduled after mid-pregnancy screening ultrasound even though they both also had a 
history of CS.  
In our study, the rate of AIP was similar in cases with major PP and in cases with minor PP. There was 
also no difference in the hysterectomy rate between the groups. This finding differs from previous studies 
[13,15]. Tuzovic et al. reported that the rate of AIP was 15.2% among women with complete (or major) 
PP and 2.9% among women with incomplete (or minor) PP [15]; most hysterectomies were performed in 
women with major PP (10.6% vs. 0.7%) [15]. Bahar et al. reported similar results [13]. They showed a 
significant association with major PP, placenta accreta (OR 3.2), and hysterectomy (OR 5.1) [13]. We 
found no difference in AIP rates between major or minor PP which will have a major impact on screening 
strategy. 
The rates of major PP and minor PP were consistent with previous studies [13-16]. In fact, the only 
significant difference between these groups was the intrapartum blood loss and the gestational age at the 
time of delivery. Women with major PP had more bleeding and delivered earlier than women with minor 
PP. A few previous studies have shown that women with major PP have a higher incidence of PPH and 
more often require blood transfusions [13-16]. Results from studies that assessed the risk for preterm 
delivery associated with PP vary [13-16]. Sekiguchi et al. found a higher incidence of preterm deliveries 
among women with major PP compared to minor PP (45.1 % versus 8.8 %) [16]. Dola et al. also reported 
an increased incidence of preterm deliveries [14]. On the other hand, Bahar et al. reported that antepartum 
hemorrhage predicted preterm delivery but the rates of preterm delivery between minor PP and major PP 
groups did not differ [13]. Tuzovic et al. also reported no difference in preterm delivery rates [15]. In our 
study, women with antenatally suspected AIP were included and these women had planned CS at 34 to 35 
gestational weeks, which had an effect on the mean gestational age of the whole group. 
  
 
 
 
11 
 
Pivano et al. established a score to predict the risk of emergency CS after the first bleeding episode [25]. 
Major PP seemed to be a major contributor [25]. In our study, women with minor PP had a higher rate of 
emergency CS than women with major PP. One explanation might be that some patients with minor PP 
attempted a vaginal delivery, followed by bleeding and emergency CS. Another explanation is missed PP 
diagnosis and lack of follow-up.  
One weakness of our study was that we had follow-up only for women with placenta overlapping the 
cervix by ≥ 15mm. Women who had minor PP or major PP overlapping the cervix by less than 15 mm at 
18 to 22 gestational weeks had no follow-up after the second trimester screening.  Thus, only those cases 
who had bleeding or other symptoms such as contractions could be identified. However, if woman with 
previously undiagnosed PP was admitted to hospital because of bleeding, vaginal US was performed and 
the diagnosis of PP was registered. 
In conclusion, our results show that regardless of the type, PP is always a serious condition. Both types of 
PP have significant risk for massive postpartum hemorrhage and AIP, especially among women with 
prior CS. We have now revised our protocol with recommendation that all women who have either major 
or minor PP at mid-pregnancy screening are scheduled for follow up ultrasound scan at 32 gestational 
weeks.  
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Table 1. Baseline characteristics of women with major or minor placenta previa 
 
 
 
Major PP 
n=129 (%) 
 
Minor PP 
n=47 (%) 
p-value OR  
(95% CI) 
 
Age (years; mean) 
 
 
<35 
≥35 
34.3  
(range 22-49) 
 
68 (52.7) 
61 (47.3) 
34.6  
(range 27-47) 
 
21 (44.7) 
26 (55.3) 
 
0.792 
 
 
0.346 
 
 
 
0.73 (0.37-1.4) 
Parity (mean) 
 
 
0 
1-2 
≥3 
1.32  
(range 0-14) 
 
49 (40.0) 
59 (45.7) 
21 (16.3) 
1.06  
(range 0-5) 
 
14 (29.8) 
30 (63.8) 
3 (6.4) 
 
0.902 
 
 
0.069 
 
Risk factors for PP 
 
History of cesarean section 
History of curettage 
History of other uterine 
procedures1 
PP in previous pregnancy 
ART pregnancy 
Multiple pregnancy 
Smoking during pregnancy 
 
 
 
31 (24.0) 
32 (24.0) 
6 (4.7) 
 
5 (3.9) 
32 (24.8) 
5 (3.9) 
9 (7.0)2 
 
 
16 (34.0) 
16 (34.0) 
3 (6.4) 
 
2 (4.3) 
6 (12.8) 
1 (2.1) 
6 (12.8) 
 
 
0.184 
0.224 
0.702 
 
1.0 
0.086 
1.0 
0.224 
 
 
1.6 (0.79-3.4) 
1.6 (0.76-3.2) 
1.4 (0.34-5.8) 
 
1.1 (0.21-5.9) 
0.44 (0.17-1.1) 
0.54 (0.061-4.7) 
2.0 (0.66-5.8) 
 
PP=placenta previa; ART=artificial reproductive technology; OR=odds ratio; CI=confidence interval 
 
1Other uterine procedures: hysteroscopy (polyp) n=2, manual removal of placenta n=4, hysteroscopy and 
manual removal of placenta n=1, second trimester termination of pregnancy by cesarean section n=1, re-
laparotomy and uterine scar revision after cesarean section n=1  
 
2Data not available for five women 
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Table 2. Comparison of pregnancy outcomes with placenta previa diagnosed or undiagnosed at mid-
trimester ultrasound screening 
 
PP=placenta previa; IQR=interquartile range; OR=odds ratio; CI=confidence interval 
1Placenta previa was diagnosed in the mid-pregnancy screening ultrasound if placenta was overlapping 
cervix ≥ 15 mm 
2Additional treatment: uterine balloon tamponade, uterine artery ligation, uterine compression sutures, 
interventional radiology procedures, peripartum hysterectomy 
3Postpartum complication: wound/uterine/pelvic/urinary bladder infections, urinary bladder laceration, 
thrombosis, disseminated intravascular coagulation, ileus, re-laparotomy, hysteroscopy due to tamponade 
balloon rupture 
 PP diagnosed1 
n=144 (%) 
 
PP undiagnosed1 
n=32 (%) 
p-value4 OR  
(95% CI) 
Type of PP 
 
    Minor 
    Major 
 
 
 
27 (18.8) 
117 (81.3) 
 
 
20 (62.5) 
12 (37.5)   
 
 
<0.0001 
 
 
 
7.2 (3.2-17) 
Gestational age at 
delivery (d) 
[Median (IQR)] 
 
    <32 
    32+0-36+6 
    ≥37 
 
258 (245-266) 
 
 
 
9 (6.3) 
67 (46.5) 
68 (47.2) 
261 (252-267) 
 
 
 
0 
13 (40.6) 
19 (59.4) 
0.088 
 
 
 
0.225 
 
Blood loss (ml) 
[Median (IQR)] 
1250 (710-2000) 
 
 
1050 (650-1763) 
 
 
0.343  
Abnormally invasive 
placenta 
 
24 (16.7) 2 (6.3) 0.173 0.33 (0.075-1.5) 
Need for any 
additional 
treatment2 
 
53 (36.8) 6 (18.8) 0.050 0.40 (0.15-1.0) 
Hysterectomy 13 (9.0) 2 (6.3) 
 
1.0 0.67 (0.14-3.1) 
Postpartum 
complication3 
 
22 (15.3) 1 (3.1) 0.082 0.18 (0.023-1.4) 
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4The chi-squared test or Fisher’s exact test was used for comparison of categorical variables between 
groups; continuous variables were analysed by Mann-Whitney U test after Shapiro-Wilk test evaluation 
of data normality 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
18 
 
Table 3. Women with placenta previa and abnormally invasive placenta 
 Women with  
abnormally invasive placenta 
n=26 (%) 
 
Age (years; mean) 36.1 (range 28-43)  
 
Parity (mean) 
0 
1 
≥2 
2.6 
2 (7.7) 
9 (34.6) 
15 (57.7) 
 
Risk factors for placenta previa 
History of cesarean section 
History of curettage 
History of miscarriage 
History of induced abortion 
History of other uterine procedures1 
Placenta previa in previous pregnancy 
ART pregnancy 
Multiple pregnancy 
Smoking during pregnancy 
 
19 (73.1) 
12 (46.2) 
12 (46.2) 
9 (34.6) 
2 (7.7) 
2 (7.7) 
1 (3.8) 
0 
0 
 
Type of PP 
Minor 
Major 
 
7 (26.9) 
19 (73.1) 
 
Gestational age at delivery (weeks) 
<32 
32+0 - 36+6 
≥37 
34+6 (range 22+3 -39+5) 
4 (15.4) 
14 (53.8) 
8 (30.8) 
 
Mode of delivery 
Vaginal 
Cesarean Section 
   Elective 
   Emergency 
 
0 
26 (100) 
22 
4 
 
Blood loss (ml; mean) 
<1500ml 
1500-2499ml 
2500-4999ml 
≥5000ml 
3249 (range 150-12 000) 
6 (23.1) 
7 (26.9) 
4 (15.4) 
9 (34.6) 
 
Any additional treatment modality 26 (100) 
 
Hysterectomy 15 (57.7) 
 
Postpartum complication 9 (34.6) 
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ART=artificial reproductive technology; PP=placenta previa 
 
1Other uterine procedures: manual removal of placenta (n=1), manual removal of placenta and 
hysteroscopy (n=1) 
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Table 4. Selected pregnancy- and delivery- associated characteristics of women with major or minor 
placenta previa 
 
PP=placenta previa; IQR=interquartile range; OR=odds ratio; CI=confidence interval 
 Major PP 
n=129 (%) 
Minor PP 
n=47 (%) 
 
p-value3 OR  
(95% CI) 
Antepartum bleeding 
 
89 (69.0) 38 (80.9) 0.120 1.9 (0.84-4.3) 
Gestational age at delivery (d) 
[median (IQR)] 
<32 
32+0-36+6 
≥37 
 
257 (245-266) 
 
8 (6.2) 
60 (46.5) 
61 (47.3) 
260 (253-268) 
 
1 (2.1) 
20 (42.6) 
26 (55.3) 
0.035 
 
0.430 
 
 
Mode of delivery 
Vaginal 
Cesarean section 
   Elective 
   Emergency 
 
 
0 
 
88 (68.2) 
41 (31.8) 
 
 
1 (2.1) 
 
25 (53.2) 
21 (44.7) 
0.061 
 
 
 
0.1134 
 
 
 
 
1.7 (0.88-3.4) 
Abnormally invasive placenta 
 
19 (14.7) 7 (14.9) 0.978 1.0 (0.40-2.6) 
Blood loss (ml) 
[median (IQR)] 
<1500ml 
1500-2499ml 
2500-4999ml 
≥5000ml 
1310 (730-2000) 
 
68 (52.7) 
36 (27.9) 
16 (12.4) 
9 (7.0) 
 
850 (610-1550) 
 
35 (74.5) 
7 (14.9) 
3 (6.4) 
2 (4.3) 
0.032 
 
0.081 
 
Red blood cell transfusion 
(units; mean) 
Yes 
No 
 
1.5 (0-15) 
 
48 (37.2) 
81 (62.8) 
1.0 (0-10) 
 
13 (27.7) 
34 (72.3) 
0.210 
 
0.239 
 
 
0.65 (0.31-1.3) 
Need for any additional 
treatment1 
Peripartum hysterectomy 
Other  
 
  Uterine balloon tamponade 
  Uterine artery ligation 
  Uterine compression sutures 
  Interventional radiology 
procedure 
 
47 (36.4) 
 
12 (9.3) 
49 (38.0) 
 
34 (26.4) 
0 (0) 
3 (2.3) 
12 (9.3) 
12 (25.5) 
 
3 (6.4) 
12 (25.5) 
 
9 (19.1) 
1 (2.1) 
1 (2.1) 
1 (2.1) 
0.175 
 
0.762 
0.125 
0.60 (0.28-1.3) 
 
0.67 (0.18-2.5) 
0.56 (0.27-1.2) 
 
Any postpartum complication2 20 (15.5) 
 
3 (6.4) 
 
0.135 0.37 (0.11-1.3) 
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1 Altogether 44 patients had one additional treatment modality and 15 patients had several additional 
treatment modalities 
2Postpartum complication: wound/uterine/pelvic/urinary bladder infection, urinary bladder laceration, 
thrombosis, disseminated intravascular coagulation, ileus, re-laparotomy, hysteroscopy due to tamponade 
balloon rupture 
3The chi-squared test or Fisher’s exact test was used for comparison of categorical variables between 
groups; continuous variables were analysed by Mann-Whitney U test 
4Comparison between emergency cesarean sections and other modes of delivery 
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Figure 1. Different types of placenta previa. 
 
 
 
 
 
 
  
Complete placenta previa Partial placenta previa 
Marginal placenta previa Low-lying placenta previa 
 Major placenta previa 
Minor placenta previa 
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Figure 2. Screening protocol and follow-up for placenta previa (PP). 
 
 
 
 
Screening for PP 
at 18+0 - 21+6
gestational weeks
PP ≥15mm 
overlapping 
internal cervical os
Follow-up visit 
at 28-30 
gestational weeks
Placenta >20mm from
internal cervical os
No further
follow-up 
PP 
minor or major
Follow-up visit 
at 34 and 36 
gestational weeks
Placenta ≥1mm from 
internal cervical os 
without bleeding
Planned
vaginal delivery
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Planned
elective 
cesarean section
PP <15mm 
overlapping 
internal cervical os
No further
follow-up
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Figure 3. Flow-chart of the study population. 
 
 
 
 
PP 
N=176
PP undiagnosed 
at mid-pregnancy 
screening
N=32
Major PP 
N=12
AIP
N=4
Minor PP 
N=20
AIP
N=6
PP diagnosed 
at mid-pregnancy 
screening 
N=144
Major PP
N=117
AIP
N=15
Minor PP
N=27
AIP
N=1
PP=placenta previa; AIP=abnormally invasive placenta 
